Cardiol Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Net Income	-36.68	-28.13	-30.93	-31.64	-20.64	Upgrade
Depreciation & Amortization	0.23	0.25	0.22	0.22	0.23	Upgrade
Asset Writedown & Restructuring Costs	0.15	-	1.36	0.08	0.08	Upgrade
Stock-Based Compensation	14.28	4.17	5.54	12.61	2.81	Upgrade
Other Operating Activities	-2.1	-0.93	-9.15	-4.89	0.07	Upgrade
Change in Accounts Receivable	0.04	0.07	-0.14	-0.06	0.01	Upgrade
Change in Inventory	-	-	-	0.02	5.85	Upgrade
Change in Accounts Payable	-1.06	-1.29	4.47	2.39	1.83	Upgrade
Change in Other Net Operating Assets	0.09	0.68	1.42	-2.27	0.64	Upgrade
Operating Cash Flow	-25.06	-25.18	-27.22	-23.54	-9.13	Upgrade
Capital Expenditures	-0.02	-0.06	-0.07	-0.01	-0.04	Upgrade
Investing Cash Flow	-0.02	-0.06	-0.07	-0.01	-0.04	Upgrade
Long-Term Debt Repaid	-0.04	-0.06	-0.05	-0.05	-0.05	Upgrade
Net Debt Issued (Repaid)	-0.04	-0.06	-0.05	-0.05	-0.05	Upgrade
Issuance of Common Stock	21.53	-	-	98.72	17.43	Upgrade
Other Financing Activities	-2.65	-	-	-5.23	-1.09	Upgrade
Financing Cash Flow	18.84	-0.06	-0.05	93.44	16.3	Upgrade
Foreign Exchange Rate Adjustments	1.89	0.76	2.92	-0.01	-0.06	Upgrade
Net Cash Flow	-4.35	-24.54	-24.43	69.87	7.07	Upgrade
Free Cash Flow	-25.08	-25.24	-27.3	-23.55	-9.17	Upgrade
Free Cash Flow Margin	-	-	-	-29904.22%	-	Upgrade
Free Cash Flow Per Share	-0.35	-0.39	-0.44	-0.55	-0.31	Upgrade
Levered Free Cash Flow	-11.86	-14.99	-20.64	-4.61	-1.61	Upgrade
Unlevered Free Cash Flow	-11.86	-14.99	-20.64	-4.61	-1.61	Upgrade
Change in Net Working Capital	1.17	0.73	0.49	-6.74	-8.32	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.